First Light Asset Management LLC Has $11.23 Million Stock Position in MiMedx Group, Inc $MDXG

First Light Asset Management LLC lessened its stake in shares of MiMedx Group, Inc (NASDAQ:MDXG) by 6.5% during the 1st quarter, HoldingsChannel.com reports. The fund owned 2,842,892 shares of the company’s stock after selling 196,449 shares during the period. MiMedx Group accounts for about 1.0% of First Light Asset Management LLC’s holdings, making the stock its 29th biggest holding. First Light Asset Management LLC’s holdings in MiMedx Group were worth $11,229,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the stock. Allspring Global Investments Holdings LLC increased its position in shares of MiMedx Group by 433.2% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 289,199 shares of the company’s stock worth $1,958,000 after purchasing an additional 234,958 shares during the last quarter. Hillsdale Investment Management Inc. acquired a new stake in shares of MiMedx Group in the 4th quarter valued at approximately $7,134,000. Vanguard Group Inc. boosted its holdings in shares of MiMedx Group by 5.6% in the 4th quarter. Vanguard Group Inc. now owns 7,184,262 shares of the company’s stock valued at $48,637,000 after buying an additional 382,623 shares during the last quarter. OP Asset Management Ltd bought a new position in shares of MiMedx Group in the first quarter valued at $2,406,000. Finally, Paradigm Capital Management Inc. NY grew its stake in shares of MiMedx Group by 39.1% in the first quarter. Paradigm Capital Management Inc. NY now owns 3,410,300 shares of the company’s stock valued at $13,471,000 after buying an additional 959,100 shares in the last quarter. 79.15% of the stock is owned by institutional investors and hedge funds.

MiMedx Group Price Performance

MDXG opened at $4.20 on Monday. MiMedx Group, Inc has a fifty-two week low of $3.03 and a fifty-two week high of $7.99. The company has a debt-to-equity ratio of 0.07, a quick ratio of 4.81 and a current ratio of 5.39. The company has a market capitalization of $625.59 million, a P/E ratio of 21.00 and a beta of 1.45. The stock has a fifty day moving average of $3.86 and a 200-day moving average of $4.30.

MiMedx Group (NASDAQ:MDXG) last announced its earnings results on Wednesday, April 29th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.02. MiMedx Group had a net margin of 7.88% and a return on equity of 21.03%. The company had revenue of $58.99 million during the quarter, compared to analysts’ expectations of $65.80 million. On average, equities analysts expect that MiMedx Group, Inc will post -0.09 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on MDXG. Wall Street Zen downgraded shares of MiMedx Group from a “buy” rating to a “hold” rating in a report on Saturday, May 2nd. Citizens Jmp lowered their price objective on shares of MiMedx Group from $7.00 to $6.00 and set a “market outperform” rating on the stock in a research note on Thursday, April 30th. Weiss Ratings cut shares of MiMedx Group from a “sell (d+)” rating to a “sell (d)” rating in a report on Monday, May 18th. Finally, Craig Hallum cut their target price on shares of MiMedx Group from $10.00 to $7.00 and set a “buy” rating for the company in a research note on Friday, April 17th. Six equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, MiMedx Group presently has an average rating of “Moderate Buy” and a consensus target price of $8.50.

MiMedx Group Company Profile

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.